Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Advanced Therapeutics in the Treatment of Hidradenitis Suppurativa
Description
The session focused on the advanced treatment options for Hidradenitis Suppurativa (HS), highlighting its complex pathophysiology and clinical presentation. HS is more prevalent than previously thought, affecting around 1-4% of the population, with significant racial disparities in diagnosis and treatment access. The speaker emphasized the evolving understanding of HS, including its phenotypes, and the importance of personalized treatment strategies based on disease severity and presentation. Various therapies were discussed, ranging from lifestyle modifications and topical treatments for mild cases to advanced biologics like anti-TNF and IL-17 inhibitors for moderate to severe HS. Recent research has shown promising results for medications like adalimumab and infliximab, while newer agents such as ruxolitinib and GLP-1 agonists are being explored. The speaker also discussed the management of acute flares, using intralesional corticosteroids and antibiotics as necessary. Overall, the treatment approach should be tailored to individual patient needs, with ongoing dialogue about expectations and response to therapy. Resources, including the HS Foundation, were recommended for further support and information.
View moreConclusions
- Hidradenitis suppurativa (HS) is more prevalent than previously thought, with significant racial disparities in diagnosis and access to care.
- There is a complex interplay of genetics, immune response, and environmental factors in HS pathophysiology.
- Mild and severe forms of HS require different treatment strategies based on clinical phenotypes.
- Current medications offer a range of effective treatments for mild to severe HS, including topical treatments, antibiotics, and biologics.
- Topical ruxolitinib shows promise as an effective treatment for mild HS with substantial patient improvement rates.
- Biologics such as adalimumab and secukinumab are effective for moderate to severe HS, with dose adjustments often necessary for optimal results.
- Emerging therapies and JAK inhibitors are entering the treatment landscape, offering additional options for patients who have failed other therapies.
- Close monitoring for safety and efficacy is essential when using advanced therapies in HS management.
- Jemec GB. NEJM 2012; 366:158-164
- Vlassiva N, et al. AAD 2012; P4822
- Pink AE, et al. JID 2011; 131:1568-1570
- Anthony et al. Cureus 2023; 15(6): e41190
- Krueger et al. BJD 2024; 2: 149-162
- Zouboulis et al. JEADV 2015; 29:619-644
- Gisondi et al. JEADV 2023
- Katugampola et al. BJD 2007; 156: 945-950
- Pink et al. JID 2012; 132(10): 2459-2461
- Sun et al. JAMA Dermatology 2023; 159(9): 930-938
- Kimball AB et al. JEADV 2016; 30(6): 989-994
- Wang and Micheletti JAAD 2019; 82(2): 507-510
- Demase et al J Clin Med 2023; 12(13): 4382
- Jyssum et al. Rheumatology (Oxford) epub Sept 2023
- van Huizan et al. J Invest Dermatol epub Nov 2023
- Kimball et al. NEJM Evidence 2024; 3(3)
- Alavi et al. SKIN The Journal of Cutaneous Medicine 2023; 7 (6), s286
- Kirby et al. JAAD 2023; 90(3): 521-529
- Nosrati et al JAMA Dermatology 2024; pub online 2/14/24
- Holcomb et al. Expert Opinion on Drug Safety 2021; 20(10): 1147-1161
- Blok et al. BJD 2016; 174(4): 839-46
- Jiang et al. BJD 2022; 187(3): 417-419
- Kimball et al. JEADV 2023; 37(10): 2098-2108
- Kim et al. J Allergy Clin Immunol 2023; 152(3): 656-666